Public release date: 19-Sep-2013 [ | E-mail | Share ] Contact: Kathy Ridgely Beal kbeal@acmg.net 301-238-4582 American College of Medical Genetics September 19, 2013 Bethesda, MD Genetic tests can now tell us whether we are at increased risk of various cancers, heart or kidney disease, asthma and a number of other conditions. Other genetic tests can tell whether you will respond to certain medicines or be harmed by side effects linked to your genetic code. But harnessing that information to benefit individual patients and prevent illnesses in others will require that doctors have access to genomic information for each patient. As health records are converted to digital form, the most likely place to store and retrieve genomic information will be Electronic Health Records (EHR). But when and how that happens will depend on having good models to build upon. Now, in the first collection of its kind, the October 2013 issue of Genetics in Medicine, the official peer-reviewed journal of the American College of Medical Genetics and Genomics, provides a series of research articles detailing challenges and solutions for integrating genomic data into EHR. The issue features the insights of research teams actively engaged in integrating genomic medicine into clinical … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, announced today the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol BIND on September 20, 2013. In addition, BIND has granted the underwriters a 30-day option to purchase up to an additional 705,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on September 25, 2013, subject to customary closing conditions. Credit Suisse (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel Nicolaus & Company, Incorporated and JMP Securities LLC are acting as co-managers. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission on September 19, 2013. The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the terms … Continue reading →

REDWOOD CITY, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that it has started a Phase 1b/2 clinical trial of its anti-cancer stem cell product candidate, demcizumab (OMP-21M18) in ovarian cancer. The trial will enroll patients at the MD Anderson Cancer Center in Houston, TX, and is being funded in part under an ovarian cancer National Cancer Institute SPORE Grant Program. In this Phase 1b/2 trial, demcizumab is being tested in combination with paclitaxel in patients with platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Following a Phase 1b safety run-in, a Phase 2 clinical trial will proceed in these patients. The primary endpoints of the Phase 2 part of the trial will be to determine the progression-free survival and response rate of the novel demcizumab with paclitaxel combination. Key secondary and exploratory endpoints include overall survival, biomarker endpoints and safety. Dr. Robert Coleman, Professor & Vice Chair, Clinical Research, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX, and the Principal Investigator who treated the first patient … Continue reading →

Stem Cell Therapy Treatment for Autism with MR by Dr Alok Sharma, Mumbai, India Improvement seen in just 3 months after Stem Cell Therapy Treatment for Autism with MR by Dr Alok Sharma, Mumbai, India After Stem Cell Therapy 1. Her sitting tolerance has improved from 15... By: Neurogen Brain and Spine Institute … Continue reading →

Stem Cell Therapy Treatment for Cerebellar Ataxia by Dr Alok Sharma, Mumbai, India Improvement seen in just 3 Months after Stem Cell Therapy Treatment for Cerebellar Ataxia by Dr Alok Sharma, Mumbai, India. Stem Cell Therapy done at Dr Alok... By: Neurogen Brain and Spine Institute … Continue reading →

Hitguj Stem Cell Therapy For more info log on to http://www.24taas.com Like us on https://www.facebook.com/Zee24Taas Follow us on https://twitter.com/zee24taasnews. By: Zee24Taas … Continue reading →